Literature DB >> 3109916

A trial of semiquantitative analysis of whole body bone scintigraphy in renal osteodystrophy.

T Kida, S Narita.   

Abstract

Four color processed whole body bone scintigraphy with 99mTc-methylene diphosphonate was performed in six patients on maintenance hemodialysis, and the results of semiquantitative colorimetric analysis were compared with those of a normal group. The difference between the two (control and patient group) was statistically significant (P less than 0.01). Furthermore, the effect of 1 alpha-hydroxyvitamin D3 treatment on renal osteodystrophy was evaluated by this method. The results indicated that this method provides a useful method for assessing the response of renal osteodystrophy to treatment. Two representative cases of renal osteodystrophy are presented to illustrate the usefulness of this approach to semiquantitative whole body bone scanning.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109916     DOI: 10.1007/bf00252644

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  17 in total

1.  Bone scintigraphy in renal osteodystrophy.

Authors:  P de Graaf; I M Schicht; E K Pauwels; J te Velde; J de Graeff
Journal:  J Nucl Med       Date:  1978-12       Impact factor: 10.057

2.  [Diagnosis of skeletal metastases in prostatic cancer using gamma camera (author's transl)].

Authors:  H Langhammer; R Sintermann; K Kempken; G Hör; H W Pabst; M Fendl
Journal:  Med Klin       Date:  1977-05-27

3.  Quantitative bone scanning: a method for assessing response of bone metastases to treatment.

Authors:  D L Citrin; R G Bessent; J B Tuohy; W R Greig; L H Blumgart
Journal:  Lancet       Date:  1974-06-08       Impact factor: 79.321

4.  Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans.

Authors:  A J Tofe; M D Francis; W J Harvey
Journal:  J Nucl Med       Date:  1975-11       Impact factor: 10.057

5.  Quantitative bone scintigraphy in evaluating treatment of renal osteodystrophy.

Authors:  P De Graaf; I M Schicht; J Te Velde; E K Pauwels; K Kleiverda; J De Graeff
Journal:  Neth J Med       Date:  1983       Impact factor: 1.422

6.  Observations on computerized quantitative bone scintigraphy in renal osteodystrophy.

Authors:  P de Graaf; E K Pauwels; P H Vos; I M Schicht; J te Velde; J de Graeff
Journal:  Eur J Nucl Med       Date:  1984

7.  Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.

Authors:  G Subramanian; J G McAfee; R J Blair; F A Kallfelz; F D Thomas
Journal:  J Nucl Med       Date:  1975-08       Impact factor: 10.057

8.  Evaluation of 99mTc diphosphonate kinetics and bone scans in patients with Paget's disease before and after calcitonin treatment.

Authors:  A D Waxman; S Ducker; D McKee; J K Siemsen; F R Singer
Journal:  Radiology       Date:  1977-12       Impact factor: 11.105

9.  Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.

Authors:  T Kida; Y Higuchi
Journal:  Oncology       Date:  1983       Impact factor: 2.935

10.  A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease.

Authors:  I Fogelman; R G Bessent; D Gordon
Journal:  Eur J Nucl Med       Date:  1981-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.